Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07287423

LEAP 2 Chronic EFS

Prospective, single-arm, non-randomized, unblinded, chronic feasibility study designed to evaluate the safety and performance of the AVEIR™ Conduction System Pacing (CSP) Leadless Pacemaker system.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nemocnice Na Homolce

Prague, Czechia

Location status: Recruiting

About this study

The purpose of this clinical investigation is to evaluate the chronic safety and performance of the AVEIR CSP Leadless Pacemaker system in a patient population with standard pacing indications.

Subjects participating in the study will have data collected at baseline, implant procedure, pre (hospital) discharge, and follow-up at 1 month, 2 months, 3 months, 6 months, 12 months, and every 6 months thereafter until study completion

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject must have at least one standard pacemaker indication
  • Subject must be at least 18 years of age
  • Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams
  • Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, as approved by the local EC

Exclusion criteria

  • Subject has a mechanical tricuspid valve, percutaneous tricuspid valve repair or replacement, or an implanted vena cava filter
  • Subject has evidence of tricuspid stenosis, tricuspid atresia, or presence of any condition that precludes appropriate vascular access for the study procedure
  • Subject has previous myocardial infarction
  • Subject is expected to be pacemaker dependent
  • Subject has a previous or existing lead or device in the right heart or interventricular septum (includes lead fragments, temporary pacing leads, and closure devices)
  • Subject has an active implantable electronic device that cannot be turned off during the study procedure
  • Subject has recent cardiovascular or peripheral vascular surgery within 30 days of enrollment
  • Subject has known allergy or hypersensitivity to < 1 mg of dexamethasone sodium phosphate or any blood or tissue contacting material used in the study procedure
  • Subject is unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation
  • Subject has known chronic renal insufficiency including patients on dialysis
  • Subject has an active systemic infection
  • Subject has known history or repair of an atrial septal defect, patent foramen ovale, or ventricular septal defect
  • Subject is currently participating in another clinical investigation that might impact the outcomes of the clinical investigation
  • Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with the follow-up requirements of the clinical investigation
  • Subject is unable to read or write

Treatment and study plan

AVEIR CSP Leadless Pacemaker System

Device

Patients will undergo a single or dual-chamber leadless pacemaker system implant wherein an investigational AVEIR CSP leadless pacemaker will be implanted in the right ventricle. Then, a commercial AVEIR AR leadless pacemaker may optionally be co-implanted in the right atrium, if indicated.

Primary outcomes

  1. Percentage of Participants Free From AVEIR CSP related Complications at 1-month

    Time frame: 1 month

    AVEIR CSP Leadless Pacemaker (LP) System complication-free-rate. A complication is defined as an AVEIR CSP LP device or AVEIR CSP procedure-related serious adverse event.

  2. Average AVEIR CSP LP Pacing Thresholds and Sense Amplitude Measurements at 1-month

    Time frame: 1 month

    Pacing Thresholds at 0.4 ms pulse width and sense amplitudes of the AVEIR CSP LP by capture type at 1 month.

Secondary outcomes

  1. Percentage of Participants Free From AVEIR CSP related Complications at 3-months

    Time frame: 3 months

    AVEIR CSP Leadless Pacemaker (LP) System complication-free-rate. A complication is defined as an AVEIR CSP LP device or AVEIR CSP procedure-related serious adverse event.

  2. Average AVEIR CSP LP Pacing Thresholds and Sense Amplitude Measurements at 3 months

    Time frame: 3 months

    Pacing Thresholds at 0.4 ms pulse width and sense amplitudes of the AVEIR CSP LP by capture type at 3 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Kwangdeok Lee, PhD

CONTACT

[email protected]

972-526-9673

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

LEadless Advanced Pacing 2 Chronic Early Feasibility Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2028
First posted
Dec 17, 2025
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.